Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
This is an open-label phase I/II study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab in patients with advanced lung cancer who have failed standard therapy.
Advanced Lung Cancer
DRUG: JS004 in combination with toripalimab
The incidence of adverse events (AE) and serious adverse events (SAE) were assessed, Incidence and severity of adverse events (AE) and serious adverse events (SAE) as assessed according to NCI-CTCAE 5.0, as well as abnormalities in vital signs, electrocardiogram, and laboratory tests, 2 years
OS, Duration of Response, 2 years|DOR, Duration of Response, 2 years|DCR, Disease Control Rate, 2 years|PFS, Progression-free survival, 2 years|Cmax, Maximum Plasma Concentration, 2 years|Tmax, Time to Cmax, 2 years|AUC0-t, Area under the concentration versus time curve from time 0 to the last measurable concentration, 2 years|AUC0-inf, AUC from time 0 to infinity, 2 years|Kel, Elimination rate constant, 2 years|t1/2, Elimination half life time, 2 years|CL/F, Clearance, 2 years|Vd/F, Apparent volume of distribution, 2 years|Rac, Accumulation factor, 2 years
This is an open-label phase I/II study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab in patients with advanced lung cancer who have failed standard therapy.